20 September, 2013. Biotecnol has appointed Neill Mackenzie as Chief Business and Operational Officer. Neill will also be part of the Board of Directors of Biotecnol and will coordinate the operational and business development activities of the company in accordance with the policies, goals, and objectives established by the Board.
Neill is is an experienced and internationally networked pharmaceutical executive with extensive operational, commercial, licensing and R&D background in academia, pharma and in working in biotech companies. As an Executive Director with P&L responsibilities, in listed (both the full London Stock Exchange (LSE) and the Alternative Investment Market) and private companies he has raised over $150 million equity capital from private and public funds and completed numerous deals with pharmaceutical companies globally.
Biotecnol is an immune-oncology company with a strong track-record in antibody drug development. The company has a proprietary antibody format -Tribody™- for engaging various immunological effector functions including T-cells, to destroy cancer cells. The Company is looking to strengthen this solid asset base of new agents in the immune-oncology field, by developing candidates with a dual approach involving novel targets. Biotecnol has fully integrated capabilities that allow the company to run and effectively manage its own drug development programmes, right from the antibody selection process to clinic proof of concept.
Back to news